SOHO 2021 | Novel transplant and post-transplant options in ALL
Aaron Logan, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, outlines the novel transplant and post-transplant options available for acute lymphoblastic leukemia (ALL). Allogeneic hematopoietic stem cell transplant remains the gold standard in high-risk or relapsed/refractory ALL and there are multiple types as well as alternatives. The use of alternative donors such as haploidentical donors, donors which match half of a patient’s human leukocyte antigen (HLA), and cord blood transplantation will increase access to transplantation for all patients. Additionally, Dr Logan discusses the advances in pre- and post-transplant management which have significantly improved the outcome of transplant. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
